Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.83 |
| ▸ | KDR | P35968 | 7/20 | 0.83 |
| ▸ | SRC | P12931 | 6/20 | 0.83 |
| ▸ | RET | P07949 | 2/20 | 0.83 |
| ▸ | FLT4 | P35916 | 2/20 | 0.83 |
| ▸ | BRAF | P15056 | 2/20 | 0.83 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.83 |
| ▸ | CIT | O14578 | 1/20 | 0.83 |
| ▸ | GAK | O14976 | 1/20 | 0.83 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.83 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.83 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.83 |
| ▸ | STK17B | O94768 | 1/20 | 0.83 |
| ▸ | STK10 | O94804 | 1/20 | 0.83 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319081 | 0.94 | EGFR (0.74) | EGFRKDRSRCRETFLT4 | |
| SCHEMBL11304 | 0.93 | EGFR (0.86) | EGFRKDRSRCRETFLT4 | |
| SCHEMBL30416288 | 0.93 | EGFR (0.86) | EGFRKDRSRCRETFLT4 | |
| SCHEMBL22383954 | 0.93 | EGFR (0.86) | EGFRKDRSRCRETFLT4 | |
| SCHEMBL17921472 | 0.92 | EGFR (0.71) | EGFRKDRSRCRETFLT4 | |
| SCHEMBL19154598 | 0.92 | SRC (0.80) | EGFRKDRSRCRETFLT4 | |
| SCHEMBL19220796 | 0.92 | EGFR (0.82) | EGFRKDRSRCRETFLT4 | |
| SCHEMBL22667930 | 0.91 | EGFR (0.82) | EGFRKDRSRCRETFLT4 | |
| Gefitinib SCHEMBL29351336 | 0.91 | EGFR (1.00) | EGFRKDRSRCRETFLT4 | |
| Gefitinib SCHEMBL29351046 | 0.91 | EGFR (1.00) | EGFRKDRSRCRETFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49851-E1 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| EP-3319987-B1 | NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | CODEXIS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3397618-B1 | PROCESS FOR MAKING CRYSTALLINE FORM A OF GEFITINIB | SYNTHON BV (NL) | 2020-11-18 | — | — | EP | disclosed |
| EP-3702783-A1 | METHODS FOR DETERMINING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | Analiza, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3092243-B1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-20180147279-A1 | COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION | MEDIMMUNE, LLC | 2018-05-31 | — | — | US | disclosed |
| US-9938302-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-7977347-B2 | inhibitors of epidermal growth factor receptor tyrosine kinase; anticancer; 6-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)hexanoic acid | CURIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110053963-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CAI XIONG | 2011-03-03 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100104558-A1 | Use of an EGFR Antagonist for the Treatment of Glomerolonephritis | INSERM (INETITUT NATIONAL DE LA SANTE ET LA RECHERCHE MEDICALE ) (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20090306207-A1 | Treatment of Drug-Resistant Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-12-10 | — | — | US | disclosed |
| US-20090186890-A1 | Pharmaceutical Formulation of Iressa Comprising a Water-Soluble Cellulose Derivative | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7547781-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080125448-A1 | Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104558-A1 | Use of an EGFR Antagonist for the Treatment of Glomerolonephritis | EGFR, GCGR, PTPRJ | EGFR 1/4885KDR 329/4885SRC 1013/4885 |
| US-20080125448-A1 | Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 75/4885SRC 62/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | EGFR 2341/4885KDR 4518/4885SRC 1384/4885 |
| US-20180147279-A1 | COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION | EGFR, PDCD1LG2, ERBB2 | EGFR 1/4885KDR 239/4885SRC 103/4885 |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC6 | EGFR 1/4885KDR 360/4885SRC 54/4885 |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | EGFR 1946/4885KDR 3390/4885SRC 3509/4885 |
| US-20090186890-A1 | Pharmaceutical Formulation of Iressa Comprising a Water-Soluble Cellulose Derivative | SI, RPS28, GYS1 | EGFR 3589/4885KDR 1384/4885SRC 1964/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | EGFR 802/4885KDR 860/4885SRC 503/4885 |
| US-20090306207-A1 | Treatment of Drug-Resistant Proliferative Disorders | ARSA, KSR1, RPS6KA1 | EGFR 1480/4885KDR 3108/4885SRC 2450/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | EGFR 2341/4885KDR 4518/4885SRC 1384/4885 |
| US-20110053963-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | EGFR 1/4885KDR 321/4885SRC 36/4885 |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | EGFR 763/4885KDR 3179/4885SRC 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.